SS
Sandesh Seth
Chief Executive OfficerDirector

Sandesh Seth insider trades: Actinium Pharmaceuticals (ATNM) stock purchases

Chief Executive Officer, Actinium Pharmaceuticals Last trade Dec 10, 2018 26 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
11
Open-market trades
since 2015
2
Companies
last trade 2018

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Sandesh reports to the SEC

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
Dec 10, 2018ATNM↑ Buy$4K
Jul 17, 2018ATNM↑ Buy$8K
Apr 19, 2018ATNM↑ Buy$2K
Aug 2, 2017ATNM↑ Buy$25K
Jun 15, 2017ATNM↑ Buy$6K
Jun 15, 2017ATNM↑ Buy$3K
Dec 30, 2016ATNM↑ Buy$4K
Dec 12, 2016ATNM↑ Buy$5K
Apr 18, 2016ATNM↑ Buy$30K
Dec 15, 2015RLMD↑ Buy$30K
Dec 14, 2015RLMD↑ Buy$31K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Sandesh Seth's insider trades

Sandesh Seth is Chief Executive Officer at Actinium Pharmaceuticals (ATNM). Since Dec 14, 2015, Sandesh has reported 11 open-market purchases worth $148K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (13 filings), other transactions (3 filings), shares withheld for taxes (1 filing), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ATNM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.